title: A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
abstract: There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss with minimal hypoglycemia. In addition, there are significant data with dipeptidyl peptidase 4 (DPP-4) inhibitors showing efficacy comparable to sulfonylureas but with weight neutral effects and reduced risk for hypoglycemia. However, over the recent past there have been concerns reported regarding the long-term consequences of using such therapies, and the issues raised are in regard to the potential of both classes to promote acute pancreatitis, to initiate histological changes suggesting chronic pancreatitis including associated preneoplastic lesions, and potentially, in the long run, pancreatic cancer. Other issues relate to a potential risk for the increase in thyroid cancer. There are clearly conflicting data that have been presented in preclinical studies and in epidemiologic studies. To provide an understanding of both sides of the argument, we provide a discussion of this topic as part of this two-part point-counterpoint narrative. In the point narrative below, Dr. Butler and colleagues provide their opinion and review of the data to date and that we need to reconsider the use of incretin-based therapies because of the growing concern of potential risk and based on a clearer understanding of the mechanism of action. In the counterpoint narrative following the contribution by Dr. Butler and colleagues, Dr. Nauck provides a defense of incretin-based therapies and that the benefits clearly outweigh any concern of risk.
authors: Larry L. Hillblom Islet Research Center, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA.
authors: Peter C
authors: PC
authors: Butler
authors: Michael
authors: M
authors: Elashoff
authors: Robert
authors: R
authors: Elashoff
authors: Edwin A M
authors: EA
authors: Gale
mesh_terms: D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000627:therapeutic use*; D018027:Receptors, Glucagon / Q000819:agonists
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D018027:Receptors, Glucagon
references: JAMA Intern Med. 2013 Apr 8;173(7):534-9
references: 23440284
references: Lancet. 2010 Apr 24;375(9724):1447-56
references: 20417856
references: Diabetologia. 2009 Oct;52(10):1975-82
references: 19688335
references: Ann Pharmacother. 2012 Nov;46(11):1547-53
references: 23136352
references: Gastroenterology. 2011 Jul;141(1):150-6
references: 21334333
references: Diabetologia. 2010 Jan;53(1):153-9
references: 19756486
references: Pancreatology. 2009;9(1-2):45-54
references: 19077454
references: Diabetes. 2013 Jul;62(7):2595-604
references: 23524641
references: Gastroenterology. 2011 Jul;141(1):20-3
references: 21723985
references: Diabetes. 2012 May;61(5):1243-9
references: 22338093
references: Diabetes Obes Metab. 2011 Jun;13(6):559-66
references: 21320263
references: Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86
references: 20923958
references: Diabetes Obes Metab. 2010 Sep;12(9):766-71
references: 20649628
references: Diabetes. 2012 May;61(5):986-8
references: 22517653
references: Endocrinology. 2000 Dec;141(12):4600-5
references: 11108273
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E253-64
references: 22589391
references: Diabetes. 2009 Jul;58(7):1604-15
references: 19403868
references: J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5
references: 9308706
references: Diabetes Obes Metab. 2013 May;15(5):417-26
references: 23163898
references: Diabetes Care. 2010 Nov;33(11):2349-54
references: 20682680
references: Endocrinology. 2010 Apr;151(4):1473-86
references: 20203154
references: J Clin Endocrinol Metab. 2012 Jan;97(1):121-31
references: 22031513
references: Cancer. 1984 Apr 15;53(8):1790-2
references: 6697317
references: Curr Med Res Opin. 2009 Apr;25(4):1019-27
references: 19278373
references: Diabetes. 2009 Sep;58(9):2148-61
references: 19509017
references: J Pathol. 2005 Jan;205(2):248-54
references: 15641021
references: Nat Biotechnol. 2008 May;26(5):479-80
references: 18464758
references: Diabetes. 2012 May;61(5):1250-62
references: 22266668
references: Annu Rev Pathol. 2008;3:157-88
references: 18039136
references: Endocr Pract. 2012 Jul-Aug;18(4):472-7
references: 22440997